KLRS · Kalaris Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $7.57M | - | $36.02M | $8.44M | $6.03M | - | - | $93.0K | $12.17M | - |
| SG&A | $4.26M | - | $3.62M | $3.82M | $4.32M | - | $5.88M | $7.17M | $10.66M | - |
| Total Operating Expenses | $11.83M | - | $12.74M | $12.26M | $10.35M | - | - | $7.77M | $32.30M | - |
| D&A | $10.0K | - | - | - | - | - | - | - | - | - |
| Operating Income | ($11.83M) | - | ($12.74M) | ($12.26M) | ($10.35M) | - | ($5.72M) | ($7.77M) | ($32.30M) | - |
| Interest Expense | $0 | - | $815.0K | $499.0K | $78.0K | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | $0 | $0 | $0 | - |
| Net Income | ($10.86M) | - | ($11.89M) | ($11.35M) | ($10.20M) | - | ($4.13M) | ($6.08M) | ($30.30M) | - |
| EPS - Basic | ($0.46) | - | ($0.64) | ($0.61) | ($2.52) | - | ($0.92) | ($1.15) | ($5.98) | - |
| EPS - Diluted | ($0.46) | - | ($0.64) | ($0.61) | ($2.52) | - | ($0.92) | ($1.15) | ($5.98) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $34.43M | $98.05M | $42.39M | $88.43M | $100.97M | $118.29M | $116.86M | $104.74M | $86.04M | $90.12M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $905.0K | $1.28M | $494.0K | $3.68M | $2.37M | $247.0K | $51.0K | $110.0K | $765.0K | $6.76M |
| Current Assets | $98.47M | $118.81M | $78.18M | $91.65M | $102.18M | $118.55M | $122.53M | $129.94M | $141.48M | $187.63M |
| Total Assets | $109.81M | $121.74M | $81.17M | $92.84M | $103.09M | $118.55M | $122.53M | $130.99M | $144.14M | $190.80M |
| Current Liabilities | $8.08M | $9.71M | $6.07M | $7.65M | $7.14M | $5.24M | $1.41M | $2.36M | $7.66M | $28.37M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $41.25M | $42.92M | $39.31M | $39.73M | $39.22M | $5.24M | $1.41M | $10.70M | $23.70M | $45.02M |
| Stockholders' Equity | $68.56M | $78.81M | $41.87M | $53.12M | $63.87M | $113.31M | $121.12M | $120.29M | $120.44M | $145.78M |
| Retained Earnings | ($170.85M) | ($160.00M) | ($150.00M) | ($138.11M) | ($126.76M) | ($714.96M) | ($696.69M) | ($692.57M) | ($686.49M) | ($656.19M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($11.58M) | - | - | - | ($7.44M) | - | - | - | ($44.38M) | - |
| Investing Cash Flow | ($50.35M) | - | - | - | - | - | - | - | $40.00M | - |
| Financing Cash Flow | ($1.70M) | - | - | - | $6.58M | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -9.9% | - | -14.7% | -12.2% | -9.9% | - | -3.4% | -4.6% | -21.0% | - |
| Return on equity | -15.8% | - | -28.4% | -21.4% | -16.0% | - | -3.4% | -5.1% | -25.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 12.19 | 12.23 | 12.89 | 11.98 | 14.31 | 22.63 | 86.78 | 55.08 | 18.48 | 6.61 |
| Quick ratio | 12.19 | 12.23 | 12.89 | 11.98 | 14.31 | 22.63 | 86.78 | 55.08 | 18.48 | 6.61 |
| Cash ratio | 4.26 | 10.09 | 6.99 | 11.56 | 14.14 | 22.58 | 82.76 | 44.40 | 11.24 | 3.18 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | -15.6x | -24.6x | -132.7x | - | - | - | - | - |
| Equity multiplier | 1.60 | 1.54 | 1.94 | 1.75 | 1.61 | 1.05 | 1.01 | 1.09 | 1.20 | 1.31 |
| Liabilities / Assets | 0.38 | 0.35 | 0.48 | 0.43 | 0.38 | 0.04 | 0.01 | 0.08 | 0.16 | 0.24 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 2.0x | - | 2.6x | 0.9x | 0.5x | - | 17.7x | 15.9x | 16.5x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -14.3% | - | -122.7% | -57.7% | 67.9% | - | 87.8% | 83.6% | 25.3% | - |
| Net income growth (YoY) | -6.5% | - | -188.3% | -86.8% | 66.3% | - | 90.7% | 86.6% | 26.4% | - |
| EPS growth (YoY) | 81.7% | - | 30.4% | 47.0% | 57.9% | - | -135.9% | -139.6% | -1259.1% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 7.3% | -30.4% | -65.4% | -55.8% | -47.0% | -22.3% | -38.0% | -47.5% | -37.8% | -35.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2017-08-31.
Product / service
$9.00M totalGrant$9.00M · 100.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Kalaris Therapeutics against the 5 most active filers in the same SIC group.